Following on from information provided to NICE by the company in October 2017 the appraisal of Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1244 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 August 2022 | Discontinued. Following on from information provided to NICE by the company in October 2017 the appraisal of Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 29 January 2018 | Suspended. Please be advised that the Department of Health has asked NICE to carry out a Single Technology Appraisal of depatuxizumab mafodotin within its marketing authorisation for treating recurrent, EGFR amplified glioblastoma. However, the company have advised that their INTELLANCE 2 clinical study has not met its primary endpoint and they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. |
| 25 September 2017 - 23 October 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 20 October 2017 | Please note this scoping exercise has now been suspended pending confirmation of trial reporting and regulatory submission timelines. Please do not submit comments on this topic. We apologise for any inconvenience this may cause. |
For further information on our processes and methods, please see our CHTE processes and methods manual